The effect of modified holmium laser enucleation of the prostate in patients with large-volume benign prostatic hyperplasia and the effect on urethral function, pain mediators, epidermal growth factor and prostate specific antigen
10.3760/cma.j.cn115455-20201222-01858
- VernacularTitle:改良钬激光前列腺剜除术治疗大体积良性前列腺增生效果及对尿道功能、疼痛介质、表皮生长因子和前列腺特异性抗原的影响
- Author:
Song YU
1
;
Guanghai YU
;
Hao DU
Author Information
1. 大连市中心医院泌尿外科，大连 116033
- Keywords:
Prostatic hyperplasia;
Laser therapy;
Prostatectomy;
Pain;
Retrospective studies
- From:
Chinese Journal of Postgraduates of Medicine
2022;45(3):226-232
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of modified holmium laser enucleation of the prostate (HoLEP) in patients with large-volume benign prostatic hyperplasia (BPH), and the effect on urethral function, pain mediators, epidermal growth factor (EGF) and prostate specific antigen (PSA).Methods:The clinical data of 83 patients with large-volume BPH in Dalian Central Hospital from October 2019 to April 2021 were retrospectively analyzed. Among them, 42 patients were treated with modified HoLEP (modified HoLEP group), and 41 patients were treated with transurethral resection of the prostate (TURP; TURP group). The procedure-related indexes (operative time, hospital stay, duration of urinary catheter retention, bladder flushing time and hemoglobin loss) were compared between 2 groups; the serum levels of pain mediators including substance P (SP), prostaglandin E 2 (PGE 2), calcitonin gene-related peptide (CGRP) before surgery and 1, 3 days after surgery were measured; the serum levels of EGF and PSA before surgery and 1, 2 weeks after surgery were measured; postoperative complications were counted; the maximum urinary flow rate, residual urine volume and bladder compliance before surgery and 3, 6 months after surgery were measured to assess urethral function; the improvement of symptoms before surgery and 3, 6 months after surgery were assessed by the overactive bladder symptom score scale, the international prostate symptom score scale and the quality of life index scale. Results:There was no statistical difference in operative time between 2 groups ( P>0.05); the hospital stay, duration of urinary catheter retention and bladder flushing time in modified HoLEP group were significantly shorter than those in TURP group: (4.52 ± 1.07) d vs. (5.74 ± 1.46) d, (2.87 ± 0.72) d vs. (4.84 ± 0.93) d, (18.29 ± 6.75) d vs. (28.54 ± 10.68) d, the hemoglobin loss was significantly lower than that in TURP group: (2.96 ± 0.84) g vs. (13.17 ± 5.69) g, and there were statistical differences ( P<0.01). There were no statistical differences in SP, PGE 2 and CGRP before surgery between 2 groups ( P>0.05); the SP, PGE 2 and CGRP 1 and 3 d after surgery in modified HoLEP group were significantly lower than those in TURP group, and there were statistical differences ( P<0.01). There were no statistical differences in EGF, PSA, urethral function and symptoms improvement before and after surgery ( P>0.05). The incidence of postoperative complications in modified HoLEP group was significantly lower than that in TURP group: 9.52% (4/42) vs. 29.27% (12/41), and there was statistical difference ( P<0.05). Conclusions:Modified HoLEP for the treatment of large-volume BPH patients can effectively reduce the incidence of postoperative complications, further reduce the level of pain mediators, and effectively shorten the postoperative recovery process.
